

REFERENCES

- Abeloff (2008)** :Cancer of the breast. Clinical Oncology.,4th ed. Philadelphia, Pa.: Churchill Livingstone,18:75-66..
- ACS (2006).** : *American cancer society* Breast Cancer Facts & Figures 2005-2006.
- ACS (2007)** :**American Cancer Society** Cancer Facts & Figures 2007
- Ahmedin J, Rebecca S, Elizabeth W,Yongping H, , Jiaquan X,Taylor M and Michael J(2008):** Cancer Statistics, American Cancer Society 58:71-96
- Albrektsen G, Heuch I, Hansen S, Kvale G(2005):** Breast cancer risk by age at birth, time since birth and time intervals between births: exploring interaction effects. Br J Cancer ,92:167-175.
- Alfredo (2004):** A History of Epidemiologic Methods and Concepts. Boston: Birkhauser, 301-302. Oncogene ISBN 3-7643: 6817-6818.
- Amundadottir L, Thorvaldsson S, Gudbjartsson D, Sulem P, Kristjansson K, Arnason S, Gulcher J, Bjornsson J, Kong A, Thorsteinsdottir U and Stefansson K. (2004):**Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family. PLoS Med. ;1:e65.
- Anglian Breast Cancer Study Group(2000):** Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population based series of breast cancer cases. Br J Cancer; ,10318-10383.
- Antoniou A and Easton D (2006):** Models of genetic susceptibility to breast cancer. Oncogene 5898905-5898925.
- Antoniou A, Pharoah P and Narod S (2003):**Average risks of breast

and ovarian cancer associated with BRCA1 or BRCA2 mutations detected case series unselected for family history: a combined analysis of 22 studies. *Am J Hum Genet* 111730-111772:.

Antoniou A, Pharoah P and McMullan G (2002): A comprehensive model for familial breast 7683-7686:

Armstrong K, Moye E, Williams S, Berlin J and Reynolds E (2007).

"Screening mammography in women 40 to 49 years of age: a systematic review for the American College of Physicians, *Ann. Intern. Med*, 146 (7): 516-526

Baker S, Lichtenstein P, Kaprio J and Holm N.(2005):Genetic susceptibility to prostate, breast, and colorectal cancer among Nordic twins. *Biometrics.* ;61:55–63.

Barbour and Warrenr,(2003): Understanding Breast Cancer Risk and Risk Factors. Fact Sheet Cornell University Program on Breast Cancer and Environmental Risk Factors in New York State

Barrett E, Mosca L and Collins P (2006): Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women *Am J Med* ,120-125.

Barrois M. (2004): Real-time PCR-based gene dosage assay for detecting BRCA1 rearrangements in breast-ovarian cancer families,. *Clin Genet.* .,65 (2): 131–136.

Begg C, Haile R, Borg A, Malone K, Concannon P, Thomas D, Langholz B, Bernstein L, Olsen J, Lynch C, Anton-Culver H, Capanu M, Liang X, Hummer A and Sima C(2008): Variation

of breast cancer risk among BRCA1/2 carriers JAMA. Jan 9,299(2):194-201.

Bernstein J(2008): Variation of breast cancer risk among BRCA1/2 carriers. JAMA. jan 9,299(2):194-201.

Best,BP (2009) :Nuclear DNA damage as a direct cause of aging. Rejuvenation Research ,12 (3): 199–208.

Billack B, and Monteiro A (2005): BRCA1 in breast and ovarian cancer predisposition. Cancer Lett. ep 8,227(1):1-7.

Boulton (2006): Cellular functions of the BRCA tumour-suppressor proteins Biochemical Society Transactions.,34 (5): 633–645.

Brandt PA van den, Spiegelman D, Yaun SS, Adami HO, Beeson L, Fol- som AR, Fraser G, Goldbohm RA, Graham S, Kushi L, et al.:(2000) Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 152:514-527.

Breast Cancer Information Core [BIC] Web site

Buchholz T(2009): Radiation therapy for early-stage breast cancer after breast-conserving surgery N Engl J Med. ,1360(1):63-70

Burkman R,Schlesse man J and Zieman M(2004): Safty concerns and healthy associated with oral contraception ,Amercian journal of obest and gynecol, (190):22-25.

Chang J, Hilsenbeck S and Fuqua S (2005): Genomic approaches in the management and treatment of breast cancer. Br J Cance ,61824-61892.

Chen J, Pee D, Ayyagari R, Graubard B, Schairer C, Byrne C,

- Benichou J and Gail M (2006):** Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst, 98:1215-1226 .
- Chen S and Parmigiani G (2007.):** Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. .,Apr 10,25(11):1329-1333.
- Choi D, Lee M, Bale A, Carter D , and Haffty B (2004):** Incidence of BRCA1 and BRCA2 Mutations in Young Korean Breast Cancer Patients Clin Oncol (22):1638-1645.
- Claus E,Schidkraut J ,Thompson W and Risch N (1998):** The genetic attributable risk of breast and ovarian cancer , Cancer (77): 231-824.
- Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer (2001):** Collaborative reanalysis of individual data from 52 epidemiological studies including 58,209women with breast cancer and 101,986 women without the disease. Lancet.,358:1389-1399.
- Couto E and Hemminki K. (2007):** Estimates of heritable and environmental components of familial breast cancer using family history information Br J Cancer. Jun .,4,96(11):1740-1742.
- Croce M (2008) :** Oncogenes and cancer ,New England journal of medicine 358 (5): 502–511.
- Csokay B, Tihomirova L, Stengrevics A, Sinicka O, Olah E (1999) :** Strong founder effects in BRCA1 mutation carrierbreast cancer patients from Latvia: mutation in brief no. 258. Online. Hum Mutat 14:92
- Cynthia O, Paschal W and Debu T (2004):**gene therpy , the oncologist 9:361-377

- Deng C. (2006):** BRCA1 cell cycle check poincheckpoint, genetic instability, DNA damage response and cancer evolution. *Nucleic Acids Res.* 6,34(5):1416-1426.
- Dent R, Trudeau M, Pritchard K, Hanna W and Kahn H (2007):** "Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence". *Clinical Cancer Research* (American Association for Cancer Research) 13: 4429–4434.
- Domchek S and Weber B (2006) :**Clinical management of BRCA1 and BRCA2 mutation carriers *Oncogene.*, 25 (43): 5825–5831.
- Dorum A, Hovig E, Trope C, Inganas M, Moller P (1999):** Three percent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA. *Eur J Cancer* 35:779–781.
- Durant S. and Nickoloff, J. (2005):** Good timing in the cell cycle for precise DNA repair by BRCA1. *Cell Cycle* 4 (9): 12116–12122
- Easton D, Poley K and Dunning A (2007):** Genome wide association study identifies novel breast cancer susceptibility loci. *Nature* 108447:108793.
- Emily S,Ulrika E, Bo G, Kerstin S, Håkan O and Elisabet W (2008):** Do both heterocyclic amines and omega-6 polyunsaturated fatty acids contribute to the incidence of breast cancer in postmenopausal women of the Malmö diet and cancer cohort, *The International Journal of Cancer* (UICC International Union Against Cancer) 123 (7): 1637–1643.
- Espey D, Wu X and Swan J, (2007):.**Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians

and Alaska Natives". *Cancer* **110** (10): 2119–2152.

Feinberg A (2004): The epigenetics of cancer etiology. *Semin Cancer Biol.* Dec,14(6):427-432.

Ferla R, Calò V, Cascio S, Rinaldi G, Badalamenti G, Carreca I, Surmacz E, Colucci G, Bazan V and Russo A(2007): Founder mutations in BRCA1 and BRCA2 genes *annu oncol suppl* 6vi.93-98.

Fisher B, Costantino J and Wickerham L (2005): Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. *J. Natl. Cancer Inst.* 97 (22): 1652–16562.

GÅłrski B, Byrski T, Huzarski T, Jakubowska A, Menkiszak J, Gronwald J, PluzaŁ, ska A, Bebenek M, Fischer-Maliszewska L, Grzybowska E, Narod SA, LubiŁ, ski J.(2000): Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. *Am J Hum Genet.* Jun;66(6):1963-1968. .

Gayther S, Warren W, Mazoyer S, Russell P, Harrington (1995): Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. *Nat Genet* 11:428-433

Gayther SA, Harrington P, Russell P, Kharkevich G, Garkavtseva RF, Ponder BAJ (1997) : Frequently occurring germ-line mutations of the BRCA1 gene in ovarian cancer families from Russia. *Am J Hum Genet* 60:1239–1242

- Giordano S and Hortobagyi G (2003)** :Inflammatory breast cancer: clinical progress and the main problems that must be addressed. *Breast Cancer Res.* 5 (6): 284–288.
- Gold B, Kalush F and Bergeron J, (2004)**:Estrogen receptor genotypes and haplotypes associated with breast cancer risk. *Cancer Res* 64:1889-1900
- Górski B, Byrski T, Huzarski T, Jakubowska A, Menkiszak J, Gronwald J, Pluzańska A, Bebenek M, Fischer-Maliszewska L, Grzybowska E, Narod SA and Lubiński J.(2001)**: Founder mutations in BRCA1 Poland. *Am J Hum Genet.* 69(2):461-463.
- Grzybowska E, Zientek H and Jasinska A(2000):**, High frequency of recurrent mutations in BRCA1 and BRCA2 genes in Polish families with breast and ovarian cancer. *Human Mutat.* 16: 482–490.
- Grzybowska E, Zientek H, Jasinska A, Rusin M, Kozłowski P, Sobczak K, Sikorska A, Kwiatkowska E, Gorniak L, Kalinowska E, Utracka-Hutka B, Wloch J, Chmielik Krzyszosiak W. (2002):** High frequency of recurrent mutations in BRCA1 and BRCA2 genes in Polish families with breast and ovarian cancer. *Human Mutat.* 16: 482–490.
- Haffty, D., Choi, S. Goyal, A. Silber, K. Ranieri, E. Matloff, M. Lee, M. and Nissenblatt, D(2009):** Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups *Ann Oncol.* 49(1):32-38
- Hall J, Lee M, Newman B, Morrow J, Anderson L, Huey B and King M.(1990):** Linkage of early-onset familial breast cancer to

chromosome 17q21. *Science*. ;250:1684–1689.

Haque K, Pfeiffer R, Beerman M Struewing P, Chanock P, and Bergen A (2003): Performance of high throughput DNA quantification methods. *BMC Biotechnol.* 3:20-24.

Hardy R, Mishra G and Kuh D(2008,): Body mass index trajectories and Link between body fat and the timing of puberty. *Pediatrics* 121(Suppl 3):S208-S217.

Hartge P(2003): Genes, hormones, and pathways to breast cancer. *N Engl J Med* 2003, 348:2352-2354.

Hartmann L(2005): Benign breast disease and the risk of breast cancer. *The New England Journal of Medicine* , 229-353.

Hemminki K, Granstrom C and Familial breast cancer(2003): scope for more susceptibility genes. *Breast Cancer Res Treat.* ;82:17–22.

Holt J, Thompson M, Szabo C, Robinson C, Arteaga C, King M and Jensen R (1996) :Growth retardation and tumour inhibition by BRCA1. *Nat Genet* 12:298-302

Hopper J and Carlin J (1992) :Familial aggregation of a disease consequent upon correlation between relatives in a risk factor measured on a continuous scale. *Am J Epidemiol.* ;136:1138–1147.

Hunter D, Kraft P and Jacobs K (2007): a genomewide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. *Nat Genet*; published online May 27

- International Union Against Cancer (2002):*** TNM Classification of Malignant Tumours. 6th ed. New York: WileyLiss,13141.
- Jahanzeb M (2008):*** Adjuvant trastuzumab therapy for HER2-positive breast cancer, Clin. Breast Cancer 8 (4): 324–333.
- James V, Aimee R , Saundra S, Pamela Ms, Shih C , Michael F and Robert N (2009):*** for the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Project Team BMC Cancer 24079-24084
- Jara L, Ampuero S, Seccia L, Frecuencia de cáncer de mama(2002):*** Frequency of the 185delAG mutation in the BRCA1 gene in Chilean healthy women with family history of breast cancer]. Rev Med Chil. ,130(10):1113Am J Hum Genet. 0 Jun,66(6):1963-1968
- Jeffrey N. I, Veronica I, Carey A, Patricia J, Julie O, Kathleen R. Blazer, Melanie R, Katrina J.,and Deborah J (2008):*** Limited Family Structure and BRCA Gene Mutation Status in Single Cases of Breast Cancer JAMA. 297:2587-2595.
- Joseph B and Joanna S (2010):*** [Aspirin May Reduce Breast Cancer Death Risk, Study Says](#),ABC News Medical Unit
- Kadouri L, Hubert A and Rotenberg Y(2007):*** Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations. Journal of Medical Genetics 44(7):467–471.
- Kaplowitz B(2008,):*** age at menopause in a British birth cohort. Maturitas 59(4):304-314.
- Kathleen Doheny (2008):*** Family History Ups Breast Cancer Risk Even Without BRCA Gene US news

- Kauff N, Satagopan J, Robson M, Scheuer L, Hensley M, Hudis C, Ellis N, Boyd J, Borgen P, Barakat R, Norton L, Castiel M and Nafa K, Offit K (2002):***Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. *N Engl J Med* 346 (21): 1609–1615.
- Kaufman B, Laitman Y, Gronwald J, Lubinski J and Friedman E.(2009):*** Genetic Modifiers of Risk of BRCA1- and BRCA2-Related Breast and Ovarian Cancers *Cancer Res*, (61): 5869–5874
- Kerber R and O'Brien E. (2005):*** A cohort study of cancer risk in relation to family histories of cancer in the Utah population database. *Cancer*. ,103:1906–1915.
- Khan Z, Poetter K and Park D (2008) :*** Enhanced solid phase PCR: mechanisms to increase priming by solid support primers". *Analytical Biochemistry* (375):391–393.
- King M, Rowell S and Love S (1993) :*** Inherited breast and ovarian cancer. What are the risks? What are the choices. *JAMA*.;269:1975–1980.
- Kleinsmith, L (2006):*** Principles of Cancer Biology.. Pearson Benjamin Cummings. ISBN 0-80534-003-3.
- Ku Sang Kim, Sung-Won Kim Min Hyuk Lee, Sei Hyun Ahn, Sue Kyung Park, and Korean Breast Cancer Society(2008):*** Hereditary Breast Cancer in Korea *Breast Cancer*. Jun 11(2): 101 - 195-.
- Lacroix M (2006):*** Significance, detection and markers of disseminated breast cancer cells". *Endocrine-related Cancer* 13 (4): 1033–1037.

- Lacroix M and Eclercq G. (2005):** The "portrait" of hereditary breast cancer. *Breast Cancer Res Treat.* Feb;89(3):297-304.
- Laura N. Burga, Nadine M. Tung, Susan L. Troyan, Mihnea Bostina, Panagiotis A. Konstantinopoulos, Helena Fountzilas, Dimitrios Spentzos, Alexander Miron, Yosuf A. Yassin, Bernard T. Lee and Gerburg M. Wulf, (2009):** Altered Proliferation and Differentiation Properties of Primary Mammary Epithelial Cells from BRCA1 Mutation Carriers ,*Cancer Research* ,1269-1273
- Laurance and Jeremy (2006):.** Breast cancer cases rise 80% since Seventies the Independent (Health Editor, Health Correspondent Retrieved on 10-09.
- Lichtenstein P, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A and Hemminki K (2000):** Environmental and heritable factors in the causation of cancer – analyses of cohorts of twins from Sweden, Denmark, and Finland. *N Engl J Med.*;343:78–85.
- Lohr K (2002):** Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force *Ann. Intern. Med.* 137 (1): 59–69.
- Lorenzo B, Hemminki K. (2005) :** Familial lung cancer and aggregation of smoking habits: a simulation of the effect of shared environmental factors on the familial risk of cancer. *Cancer Epidemiol Biomarkers Prev.* 14:1738–1740.
- Louise Chang(2008) :** Family history Increased Risk Even Without Gene Mutations Linked to Breast Cancer . *American cancer society* 6:587-600.
- lu J, Wei Q and Bondy M (2006): .** Polymorphisms and haplotypes of the NBS1 gene are associated with risk of sporadic breast cancer in nonHispanic white women 55 years. *Carcinogenesis* 220916-

2209

Lynch H, Silva E, Snyder C and Lynch J (2008): Hereditary breast cancer: Part I. Diagnosing hereditary breast cancer syndromes. *The Breast Journal* 14 (1): 13 -31.

Madigan M, Ziegler R, Benichou J, Byrne C, Hoover R (1995): Proportion of breast cancer cases in the United States explained by well-established risk factors". *J. Natl. Cancer Inst.* 87 (22): 1681-1685. Retrieved on 2007-05-26.

Malone K, Daling J and Doody D (2006): Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. *Cancer Research* 66(16):8297–8308.

Marc J, Donald R., Herbert Y, Sylvia r, Thomas E, JoAnn E., Jixin H, Barbara V, Judith W, Robert D and Howard D. (2009): Insulin, Insulin-Like Growth Factor-I, and Risk of Breast Cancer in Postmenopausal Women *Journal of the National Cancer Institute Advance* 101(1):48-60.

Martin A and Weber B. (2000): Genetic and hormonal risk factors in breast cancer. *J Natl Cancer Inst.*; 92: 1126–1135.

Mazoyer S. (2005): Genomic rearrangements in the BRCA1 and BRCA2 genes. *Hum Mutat.* 25 (5): 415–422.

Merlo L, Pepper J, Reid B, Maley C (2006). :Cancer as an evolutionary and ecological process". *Nat Rev Cancer* 6 (12): 924–935.

Monninkhof E, Vlems F, van T ,Schuit A, Voskuil D and van F (2007): Physical activity and breast cancer: a systematic review. *Epidemiology* , (18):137-157.

Morrow M (2004): Magnetic resonance imaging in breast cancer: one

step forward, two steps back JAMA, 292 (22): 2779-2770.

Narod S and Foulkes W (2004): BRCA1 and BRCA2 and beyond, Nat. Rev. Cancer ,(4) 665–676.

Nichols H, Trenthamz A, Hampton J, Titus L, Egan K, Willett W, and Newcomb P (2006): From menarche to menopause: trends among US Women born from 1912 to 1969. Am J Epidemiol, (164):1003-1011.

Obermiller P, Tait D and Holt I (2000): Gene therapy for carcinoma of the breast: therapeutic genetic correction strategies. Breast Cancer Res 2:28-31.

Ottini L, D'Amico C, Noviello C and Lauro S(2000): BRCA1 and BRCA2 mutations in central and southern Italian patients. Breast Cancer Res. ;2(4):307-10.

Palma M, Ristori E, Ricevuto E, Giannini G and, Gulino A.(2006): BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers. Crit Rev Oncol Hematol. An,57(1):11-23.

Parkin D, Bray F, Ferlay J and Pisani P (2002): Global cancer statistic ,CA Cancer J Clin ,55 (2): 108 -174.

Perkins E, Small B, Balducci L, Extermann M, Robb C and Haley W (2007): Individual differences in well-being in older breast cancer survivors". Crit. Rev. Oncol. Hematol. 62 (1): 74–83.

Pharoah Day N, Duffy S, Easton D, Ponder B. (1997) : Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer. 71:800–809.

pukkala E and Weiderpass E(2006): time trends in socioeconomic

differences in incidence rates of cancers of the breast and female genital organs (Finland, 1971-1995).):PALB2, which Int J Cancer,5661-5681

Rahman N, Seal S and Thompson D(2007): encodes a BRCA interacting protein, is a breast cancer susceptibility gene. Nat Genet 1639:1657.

Ramon Parsons(2007): new study reveals for first time how brca1 mutations cause breast cancer Columbia University College of Nature Genetics. 212: 6305-6535

Ramus SJ, Kote-Jarai Z, Friedman LS, van der Looij M, Gayther SA, Csokay B, Ponder BAJ, et al (1997) ;Analysis of BRCA1 and BRCA2 mutations in Hungarian families with breast or breast-ovarian cancer. Am J Hum Genet 60:1242–1246

Renwick A, Thompson D and Seal S(2006): ATM mutations that cause ataxiatelangiectasia .Are breast cancer susceptibility alleles. Nat Genet, 8735-8738.

Risch H, McLaughlin J, Cole D, Rosen B, 2001): Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68:700–710

Rusiecki J, Holford T ,Zahm S and Zhang T(2005): breast cancer risk factors according to joint estrogen receptor and progesterone receptor status .Cancer Detec. Prev.29 (5):419-426.

Sambrook J, Fritsch E and Maniatis T(2001): Molecular cloning laboratory cold spring harbor laboratory press

Seal S, Thompson D and Renwick A(2006): Truncating mutations in

the Fanconi anemia J gene BRIP1 are low penetrance breast cancer susceptibility alleles. Nat Genet, 123938-123941

Smith R, Ballard R, Miglioretti D, Patnick J, Kerlikowske K (2005): Comparing the performance of mammography screening in the USA mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 11:198–200

Streuwing J, Abeliovich D, Peretz T, Avishai N, Kaback M, Collins F and Brody L (1995): The carrier frequency of the BRCA1 185delAG and the UK". Journal of medical screening 12 : 5052- 5054.

Streuwing J, Hartge P, Wacholder S, Baker S, Berlin M, McAdams M and Timmerman M (1997): The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408

Snedecor G Cochran W and Cox D(1989): statistical methods (8th) the Iowa state university press.

Syrjäkoski K, Kuukasjärvi T, Waltering K(2004): BRCA2 mutations in 154 Finnish male breast cancer patients. Neoplasia a,5415.. 5416.

Szabo C and King M (1997) : Population genetics of BRCA1 and BRCA2. Am J Hum Genet 60:1013–1020

Tammemagi C (2007) .: Racial/ethnic disparities in breast and gynecologic cancer treatment and outcomes". Curr. Opin. Obstet. Gynecol. ,19 (1): 31–61.

Tannock I, Hill R and Bristow R (2005): The Basic Science of Oncology., McGraw-Hill. ISBN 0-07138-774-779. 4th ed.

Tapia T, Smalley S, Kohen P, Muñoz A, Solis L, Corvalan A, Faundez P, Devoto L, Camus M, Alvarez M and Carvallo P (2008): Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors. *Epigenetics*. 3 (3): 157–163.

Thomas DGao DL and, Ray RM (2002). :Randomized trial of breast self-examination in Shanghai: final results J. Natl. Cancer Inst. 94 (19): 1445-1457.

Thompson D and Easton D (2004): Cancer incidence in BRCA1 mutation carriers. *J Natl Cancer Inst* 94:1358-1365

Thompson D, Easton D (2002): Variation in BRCA1 cancer risks by mutation position. *Cancer Epidemiol Biomarkers Prev* 11:329–336

Vaidyanathan K, Smita H, Ravishankar o, Umaira T,Geetashree Me and Kumaravel S (2009): BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation *Journal of Biosciences* ISSN 0250-5991 pages 333-491

Venkitaraman, A (2002): cancer susceptibility and the functions of BRCA1 and BRCA2, *Cell* ,108 (2): 171-182

Vogel K, Atchley D and Erlichman J(2008): BRCA1 and BRCA2 genetic testing in Hispanic patients: Mutation prevalence and evaluation of the BRCAPRO risk assessment model. *Journal of Clinical Oncology* 25(29):4635–4641.

Walsh T, Casadei S and Coats KH (2006): Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. *Journal of the American Medical Association*

295(12):1379–1388

Wang J, Costantino J, TanChiu E, Wickerham D , Paik S and Wolmark N(2004): Lower category benign breast disease and the risk of invasive breast cancer. J Natl Cancer Inst, 61620-

Wang S, Shao R, Pao A, Zhang S and Hung L (2002): Inhibition of cancer cell growth by BRCA2. Cancer Res13162:13114.

Wang, B, Hurov, K.,Hofmann K.and Elledge, S (2009): NBA1, a new player in the Brca1 A complex, is required for DNA damage resistance and checkpoint control. Genes Dev.,23: 729-739.

Yager J and Davidson N (2006):Estrogen carcinogenesis in breast cancer. New Engl J Med ,354 (3): 270–282.

Yassaee V ,Zeinali S, Hairchi I,Jarvandi S, Mohagheghi M,Hornby D ,Dalton Hornby D and Dalton A (2002): Novel mutations in BRCA1 and BRCA2 genes in Iranian women with early –onset breast cancer .Res ,4:R6